These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 12580646)

  • 1. Quantitative methods in pharmacovigilance: focus on signal detection.
    Hauben M; Zhou X
    Drug Saf; 2003; 26(3):159-86. PubMed ID: 12580646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A brief primer on automated signal detection.
    Hauben M
    Ann Pharmacother; 2003; 37(7-8):1117-23. PubMed ID: 12841826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statistical and graphical approaches for disproportionality analysis of spontaneously-reported adverse events in pharmacovigilance.
    Zink RC; Huang Q; Zhang LY; Bao WJ
    Chin J Nat Med; 2013 May; 11(3):314-20. PubMed ID: 23725848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department.
    Almenoff JS; LaCroix KK; Yuen NA; Fram D; DuMouchel W
    Drug Saf; 2006; 29(10):875-87. PubMed ID: 16970511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Signal selection and follow-up in pharmacovigilance.
    Meyboom RH; Lindquist M; Egberts AC; Edwards IR
    Drug Saf; 2002; 25(6):459-65. PubMed ID: 12071784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A qualitative approach to signal mining in pharmacovigilance using formal concept analysis.
    Lillo-Le Louët A; Toussaint Y; Villerd J
    Stud Health Technol Inform; 2010; 160(Pt 2):969-73. PubMed ID: 20841828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of stratification on adverse drug reaction surveillance.
    Hopstadius J; Norén GN; Bate A; Edwards IR
    Drug Saf; 2008; 31(11):1035-48. PubMed ID: 18840023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of statistical signal detection procedures in eudravigilance post-authorization data: a retrospective evaluation of the potential for earlier signalling.
    Alvarez Y; Hidalgo A; Maignen F; Slattery J
    Drug Saf; 2010 Jun; 33(6):475-87. PubMed ID: 20486730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse drug reaction or innocent bystander? A systematic comparison of statistical discovery methods for spontaneous reporting systems.
    Dijkstra L; Garling M; Foraita R; Pigeot I
    Pharmacoepidemiol Drug Saf; 2020 Apr; 29(4):396-403. PubMed ID: 32092786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are all quantitative postmarketing signal detection methods equal? Performance characteristics of logistic regression and Multi-item Gamma Poisson Shrinker.
    Berlin C; Blanch C; Lewis DJ; Maladorno DD; Michel C; Petrin M; Sarp S; Close P
    Pharmacoepidemiol Drug Saf; 2012 Jun; 21(6):622-30. PubMed ID: 21994119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential use of data-mining algorithms for the detection of 'surprise' adverse drug reactions.
    Hauben M; Horn S; Reich L
    Drug Saf; 2007; 30(2):143-55. PubMed ID: 17253879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of Spontaneously Reported Adverse Events].
    Nakamura M
    Yakugaku Zasshi; 2016; 136(4):549-56. PubMed ID: 27040337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An MCEM Framework for Drug Safety Signal Detection and Combination from Heterogeneous Real World Evidence.
    Xiao C; Li Y; Baytas IM; Zhou J; Wang F
    Sci Rep; 2018 Jan; 8(1):1806. PubMed ID: 29379048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of time-to-onset in statistical signal detection of adverse drug reactions: a comparison with disproportionality analysis in spontaneous reports from the Netherlands.
    Scholl JH; van Puijenbroek EP
    Pharmacoepidemiol Drug Saf; 2016 Dec; 25(12):1361-1367. PubMed ID: 27686554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database.
    Szarfman A; Machado SG; O'Neill RT
    Drug Saf; 2002; 25(6):381-92. PubMed ID: 12071774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Comparison Study of Algorithms to Detect Drug-Adverse Event Associations: Frequentist, Bayesian, and Machine-Learning Approaches.
    Pham M; Cheng F; Ramachandran K
    Drug Saf; 2019 Jun; 42(6):743-750. PubMed ID: 30762164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Illusions of objectivity and a recommendation for reporting data mining results.
    Hauben M; Reich L; Gerrits CM; Younus M
    Eur J Clin Pharmacol; 2007 May; 63(5):517-21. PubMed ID: 17364192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Disproportionality Analysis of Pharmacovigilance Databases in Safety Regulatory Actions: a Systematic Review.
    Dias P; Penedones A; Alves C; Ribeiro CF; Marques FB
    Curr Drug Saf; 2015; 10(3):234-50. PubMed ID: 26219291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implemented data mining and signal management systems on spontaneous reporting systems' databases and their availability to the scientific community - a systematic review.
    de Almeida Vieira Lima LM; Nunes NG; da Silva Dias PG; Marques FJ
    Curr Drug Saf; 2012 Apr; 7(2):170-5. PubMed ID: 22873501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postmarketing surveillance of potentially fatal reactions to oncology drugs: potential utility of two signal-detection algorithms.
    Hauben M; Reich L; Chung S
    Eur J Clin Pharmacol; 2004 Dec; 60(10):747-50. PubMed ID: 15619136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.